相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Evaluation of 5-Fluorouracil Pharmacokinetics in Cancer Patients with a c.1905+1G>A Mutation in DPYD by Means of a Bayesian Limited Sampling Strategy
Andre B. P. van Kuilenburg et al.
CLINICAL PHARMACOKINETICS (2012)
DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity
Chen Guang Yang et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency
Maurice C. van Staveren et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Severe fluoropyrimidine-related toxicity: clinical implications of DPYD analysis and UH2/U ratio evaluation
E. Giorgio et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
A mild phenotype of dihydropyrimidine dehydrogenase deficiency and developmental retardation associated with a missense mutation affecting cofactor binding
Sabine Weidensee et al.
CLINICAL BIOCHEMISTRY (2011)
Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer
Maarten J. Deenen et al.
CLINICAL CANCER RESEARCH (2011)
Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients
Joana Savva-Bordalo et al.
BMC CANCER (2010)
Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity
Andre B. P. van Kuilenburg et al.
HUMAN GENETICS (2010)
The Value of Dihydrouracil/Uracil Plasma Ratios in Predicting 5-Fluorouracil-related Toxicity in Colorectal Cancer Patients
M. H. Kristensen et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2010)
The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil
R. Ben Fredj et al.
PATHOLOGIE BIOLOGIE (2009)
Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment
Ursula Amstutz et al.
PHARMACOGENOMICS (2009)
A Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of 5-Fluorouracil Degradation Rate by Intact Peripheral Blood Mononuclear Cells
Alfonso M. Lostia et al.
THERAPEUTIC DRUG MONITORING (2009)
Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: A prospective clinical trial by the German 5-FU toxicity study group
Matthias Schwab et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy
Ursula Amstutz et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2008)
Pharmacokinetics of 5-fluorouracil in patients heterozygous for the IVS14+1G > A mutation in the dihydropyrimidine dehydrogenase gene
A. B. P. van Kuilenburg et al.
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS (2008)
Severe or lethal toxicities upon capecitabine intake: is DPYD genetic polymorphism the ideal culprit?
Cedric Mercier et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2007)
SSCP screening of the dihydropyrimidine dehydrogenase gene polymorphisms of the japanese population using a semi-automated electrophoresis unit
Yoshihiro Okamoto et al.
BIOCHEMICAL GENETICS (2007)
Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related toxicity
Nicolas Magne et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2007)
5-fluorouracil-related severe toxicity: A comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency
M. Boisdron-Celle et al.
CANCER LETTERS (2007)
HPLC-electrospray tandem mass spectrometry for rapid determination of dihydropyrimidine dehydrogenase activity
Andre B. P. van Kuilenburg et al.
CLINICAL CHEMISTRY (2007)
The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients
Zhi Wei Zhou et al.
CHEMOTHERAPY (2007)
Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance
Alain Morel et al.
MOLECULAR CANCER THERAPEUTICS (2006)
A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity
Guido Bocci et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy
Joseph Ciccolini et al.
THERAPEUTIC DRUG MONITORING (2006)
Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians
Lori Kay Mattison et al.
CLINICAL CANCER RESEARCH (2006)
Toxic death-case after capecitabine plus oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency
J Ciccolini et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity:: Pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil
LK Mattison et al.
CLINICAL CANCER RESEARCH (2006)
Activity of pyrimidine degradation enzymes in normal tissues
A. B. P. van Kuilenburg et al.
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS (2006)
Methylation of the DPYD promoter:: An alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients
HH Ezzeldin et al.
CLINICAL CANCER RESEARCH (2005)
Sensitive MS/MS-liquid chromatography assay for simultaneous determination of tegafur, 5-fluorouracil and 5-fluorodihydrouracil in plasma
G Remaud et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2005)
An accurate dihydrouracil/uracil determination using improved high performance liquid chromatography method for preventing fluoropyrimidines-related toxicity in clinical practice
G Remaud et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2005)
Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals
K Seck et al.
CLINICAL CANCER RESEARCH (2005)
Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test
LK Mattison et al.
CLINICAL CANCER RESEARCH (2004)
Mutations in exon 14 of dihydropyrimidine dehydrogenase and 5-Fluorouracil toxicity in Portuguese colorectal cancer patients
N Salgueiro et al.
GENETICS IN MEDICINE (2004)
Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels
H Jiang et al.
BRITISH JOURNAL OF PHARMACOLOGY (2004)
A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity
J Ciccolini et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2004)
Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells
T Noguchi et al.
CLINICAL CANCER RESEARCH (2004)
Detailed Analysis of Five Mutations in Dihydropyrimidine Dehydrogenase Detected in Cancer Patients With 5-fluorouracil-related Side Effects
Eva Gross et al.
HUMAN MUTATION (2003)
Use of pyrosequencing to detect clinically relevant polymorphisms in dihydropyrimidine dehydrogenase
R Ahluwalia et al.
CLINICAL CHEMISTRY (2003)
Mutational analysis of the human dihydropyrimidine dehydrogenase gene by denaturing high-performance liquid chromatography
J Fischer et al.
GENETIC TESTING (2003)
Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer
A Di Paolo et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2002)
High prevalence of the IVS14+1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity
ABP van Kuilenburg et al.
PHARMACOGENETICS (2002)
Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency:: High prevalence of the IVS14+1G>A mutation
ABP Van Kuilenburg et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Simple liquid chromatographic method for the determination of uracil and dihydrouracil plasma levels: a potential pretreatment predictor of 5-fluorouracil toxicity
MB Garg et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2002)
A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency
H Ezzeldin et al.
ANALYTICAL BIOCHEMISTRY (2002)
Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure
ABP van Kuilenburg et al.
BIOCHEMICAL JOURNAL (2002)
Porous graphitic carbon shows promise for the rapid screening partial DPD deficiency in lymphocyte dihydropyrimidine dehydrogenase in Chinese, Indian and Malay in Singapore by using semi-automated HPLC-radioassay
LK Liem et al.
CLINICAL BIOCHEMISTRY (2002)
High-performance liquid chromatographic assay with ultraviolet detection for quantification of dihydrofluorouracil in human lymphocytes:: application to measurement of dihydropyrimidine dehydrogenase activity
R Déporte-Féty et al.
JOURNAL OF CHROMATOGRAPHY B (2001)
Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients
A Di Paolo et al.
ANNALS OF ONCOLOGY (2001)
Rapid detection of a common dihydropyrimidine dehydrogenase mutation associated with 5-fluorouracil toxicity and congenital thymine uraciluria using fluorogenic hybridization probes
M Nauck et al.
CLINICAL BIOCHEMISTRY (2001)
Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction
MR Johnson et al.
ANALYTICAL BIOCHEMISTRY (2000)
Measurement of plasma uracil using gas chromatography-mass spectrometry in normal individuals and in patients receiving inhibitors of dihydropyrimidine dehydrogenase
DQ Bi et al.
JOURNAL OF CHROMATOGRAPHY B (2000)
分享论文
